Previous Close | 9.33 |
Open | 9.42 |
Bid | 9.44 x 1800 |
Ask | 9.45 x 2900 |
Day's Range | 9.33 - 9.58 |
52 Week Range | 8.42 - 12.40 |
Volume | |
Avg. Volume | 9,391,638 |
Market Cap | 11.316B |
Beta (5Y Monthly) | 1.19 |
PE Ratio (TTM) | 5.47 |
EPS (TTM) | 1.73 |
Earnings Date | May 08, 2023 - May 12, 2023 |
Forward Dividend & Yield | 0.48 (5.22%) |
Ex-Dividend Date | Mar 08, 2023 |
1y Target Est | 15.63 |
Subscribe to Yahoo Finance Plus to view Fair Value for VTRS
Healthcare spinoffs aren't normally seen as companies with strong growth potential. More likely than not, spinoffs stem from a division of a company that, while possibly profitable, is seeing slower growth. Embecta (NASDAQ: EMBC.V), Viatris (NASDAQ: VTRS) and GE Healthcare Technologies (NASDAQ: GEHC) are three of the bigger healthcare spinoffs in recent years.
How high of a dividend yield does a stock need to have to be considered a high-yield stock? Opinions vary. However, many investors would include any stock with a yield that's greater than that offered by 10-year U.
Over the past year, Pfizer (NYSE: PFE) made a series of acquisitions, even announcing at one point that it planned to remain "very active in deal-making." On March 13, Pfizer announced the planned blockbuster acquisition of cancer specialist Seagen (NASDAQ: SGEN) for a massive $43 billion in cash. This move, expected to close by year-end or early 2024, will likely improve Pfizer's prospects, and it is only the latest in a series of important and successful strategic decisions the company's management has made.